Reducing Re-fractures Post Percutaneous Kyphoplasty: The Impact of Zoledronic Acid with Calcium and Vitamin D3 in Osteoporotic Patients
CONCLUSIONS: Zoledronic acid in combination with calcium carbonate and vitamin D3 effectively enhances bone health in osteoporosis patients, warranting its clinical recommendation. This regimen shows promise for improving patient outcomes in osteoporosis management.PMID:38518159 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 22, 2024 Category: Complementary Medicine Authors: Weiqian Wu Wenbiao Zheng Weiwei Pan Fanghu Chen Langqing Jiang Source Type: research
Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Pagets disease of bone
Conclusions
Genetic testing for pathogenic SQSTM1 variants coupled with intervention with ZA is well tolerated and has favourable effects on the progression of early PDB.
Trial registration number
ISRCTN11616770. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Phillips, J., Subedi, D., Lewis, S. C., Keerie, C., Cronin, O., Porteous, M., Moore, D., Cetnarskyj, R., Ranganath, L., Selby, P. L., Turgut, T., Hampson, G., Chandra, R., Ho, S., Tobias, J., Young-Min, S., McKenna, M. J., Crowley, R. K., Fraser, W. D., T Tags: Open access, ARD, Miscellaneous Source Type: research
Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma
Cancer Immunol Immunother. 2024 Mar 2;73(4):62. doi: 10.1007/s00262-024-03652-2.ABSTRACTHow to increase the response of immune checkpoint inhibitors (ICIs) is a challenge. In clinical, we found that Zoledronic acid (ZA) may increase the anti-tumor effect of immunotherapy for hepatocellular carcinoma (HCC). To explore the underlying mechanism, we established a mouse model of HCC by subcutaneously injecting Hepa1-6 cell line. The result showed that the tumor volume in the ZA plus anti-PD-1 monocloning antibody (anti-PD-1 mAb) treatment groups was significantly smaller than that of control group, and the onset time of tumor i...
Source: Cancer Control - March 2, 2024 Category: Cancer & Oncology Authors: Xinru Fan Zijun Yan Yunkai Lin Qing Wang Li Jiang Xiaomeng Yao Liwei Dong Lei Chen Tuan Zhao Jieqiong Zhao Heping Hu Hui Wang Source Type: research
Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma
AbstractHow to increase the response of immune checkpoint inhibitors (ICIs) is a challenge. In clinical, we found that Zoledronic acid (ZA) may increase the anti-tumor effect of immunotherapy for hepatocellular carcinoma (HCC). To explore the underlying mechanism, we established a mouse model of HCC by subcutaneously injecting Hepa1-6 cell line. The result showed that the tumor volume in the ZA plus anti-PD-1 monocloning antibody (anti-PD-1 mAb) treatment groups was significantly smaller than that of control group, and the onset time of tumor inhibition was even shorter than that of the anti-PD-1 mAb group. Using flow cyto...
Source: Cancer Immunology, Immunotherapy - March 2, 2024 Category: Cancer & Oncology Source Type: research
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects
ConclusionItalian oncologists showed a high attitude in prescribing bisphosphonates or denosumab at the time of diagnosis of bone metastases, with a large application of preventive measures of side effects. Further studies are needed to investigate some controversial aspects, such as optimal drug treatment duration and long-term drug schedules. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - March 1, 2024 Category: Cancer & Oncology Source Type: research
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages
In conclusion, ODX does not inhibit osteoclast formation but inhibits osteoclastic bone resorption by decreasing osteoclast numbers through enhanced cell death of mature osteoclasts. (Source: Investigational New Drugs)
Source: Investigational New Drugs - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Zoledronic acid enhances tumor growth and metastatic spread in a mouse model of jaw osteosarcoma
CONCLUSION: The use of bisphosphonates in the therapeutic strategy for JO should be further explored, as should the role of bone resorption in the pathophysiology of the disease.PMID:38376129 | DOI:10.1111/odi.14897 (Source: Cancer Control)
Source: Cancer Control - February 20, 2024 Category: Cancer & Oncology Authors: Than-Thuy Nham Romain Guiho R égis Brion J érôme Amiaud B énédicte Brounais Le Royer Anne Gomez-Brouchet Fran çoise Rédini H élios Bertin Source Type: research
Inhibition of cysteine protease disturbs the topological relationship between bone resorption and formation in vitro
ConclusionThese new findings help clarify coupling mechanisms and will contribute to the development of new drugs for osteoporosis. (Source: Journal of Bone and Mineral Metabolism)
Source: Journal of Bone and Mineral Metabolism - February 20, 2024 Category: Orthopaedics Source Type: research
Effect of Intravenous Zoledronic Acid on Total Knee Replacement in Patients with Symptomatic Knee Osteoarthritis and Without Severe Joint Space Narrowing: A Prespecified Secondary Analysis of the ZAP2 Trial
ConclusionThese results suggest that ZA is not protective against TKR in patients with symptomatic knee osteoarthritis and without severe JSN. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - February 19, 2024 Category: Rheumatology Authors: Guoqi Cai,
Laura L. Laslett,
Michael Thompson,
Flavia Cicuttini,
Catherine Hill,
Anita E. Wluka,
Lyn March,
Yuanyuan Wang,
Petr Otahal,
James D. Stoney,
Benny Antony,
Kathy Buttigieg,
Tania Winzenberg,
Graeme Jones,
Dawn Aitken Tags: Full Length Source Type: research
Ozone therapy effect in medication-related osteonecrosis of the jaw as prevention or treatment: microtomographic, confocal laser microscopy and histomorphometric analysis
ConclusionsOzone therapy modulated alveolar bone repair in animals treated with ZOL, mainly after surgery trauma, leading to bone formation as healing tissue.Clinical relevanceOsteonecrosis has been a challenge in dentistry, and owing to the lack of a consensus regarding therapy, studies presenting new therapies are important, and ozone has been one of the therapies explored empirically. (Source: Clinical Oral Investigations)
Source: Clinical Oral Investigations - February 16, 2024 Category: Dentistry Source Type: research
Efficacy and risk of osteonecrosis of the jaw for pamidronate, zoledronic acid, and denosumab in comparison to alendronate in multiple myeloma patients
CONCLUSION: This study shows that fracture reduction risk is comparable for all four treatments in multiple myeloma patients, but ONJ risk is lowest for alendronate and pamidronate. Overall, these data support the continued use of pamidronate and alendronate in multiple myeloma patients.PMID:38343457 | PMC:PMC10857533 | DOI:10.1080/08998280.2023.2298667 (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - February 12, 2024 Category: Universities & Medical Training Authors: Micah Browne Brittany Miles James Mackey Source Type: research
The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma
Expert Rev Hematol. 2024 Feb 6:1-8. doi: 10.1080/17474086.2024.2316090. Online ahead of print.ABSTRACTINTRODUCTION: Immunomodulatory drugs (IMiDs) are widely used in the management of newly diagnosed and relapsed/refractory multiple myeloma patients. These agents show their potential effect on myeloma bone disease (MBD), including inhibition of osteoclasts activity and effects on osteoblasts differentiation. It is unclear whether these effects are direct, which may have an impact on bone formation markers when combined with proteasome inhibitors.AREAS COVERED: This review summarizes the available evidence on the role of IM...
Source: Expert Review of Hematology - February 6, 2024 Category: Hematology Authors: Yang Liu Bo Li Xiaomin Chen Hao Xiong Chunlan Huang Source Type: research
Biomolecular fingerprints of the effect of zoledronic acid on prostate cancer stem cells: Comparison of 2D and 3D cell culture models
Arch Biochem Biophys. 2024 Feb 1;753:109920. doi: 10.1016/j.abb.2024.109920. Online ahead of print.ABSTRACTRevealing the potential of candidate drugs against different cancer types without disrupting normal cells depends on the drug mode of action. In the current study, the drug response of prostate cancer stem cells (PCSCs) to zoledronic acid (ZOL) grown in two-dimensional (2D) and three-dimensional (3D) culture systems was compared using Fourier transform-infrared (FT-IR) spectroscopy which is a vibrational spectroscopic technique, supporting by biochemical assays and imaging techniques. Based on our data, in 2D cell cul...
Source: Archives of Biochemistry and Biophysics - February 2, 2024 Category: Biochemistry Authors: G ünnur Güler Eda Acikgoz G ünel Mukhtarova Gulperi Oktem Source Type: research
Growth hormone and testosterone delay vertebral fractures in boys with muscular dystrophy on chronic glucocorticoids
ConclusionGH and testosterone each decreased VF risk in patients independent of or in combination with ZA, respectively. (Source: Osteoporosis International)
Source: Osteoporosis International - February 1, 2024 Category: Orthopaedics Source Type: research
